Effect of nirsevimab on hospitalisations for respiratory syncytial virus bronchiolitis in France, 2023–24: a modelling study-Reference-Cited by-同舟云学术

Effect of nirsevimab on hospitalisations for respiratory syncytial virus bronchiolitis in France, 2023–24: a modelling study

Published:2024-08 Issue: Volume: Page:
ISSN:2352-4642
Container-title:The Lancet Child & Adolescent Health
language:en
Short-container-title:The Lancet Child & Adolescent Health

Author:

Brault Antoine,Pontais Isabelle,Enouf Vincent,Debeuret Christine,Bloch Emma,Paireau Juliette,Rameix-Welti Marie-Anne,White Michael,Baudemont Gaëlle,Lina Bruno,Parent du Châtelet Isabelle,Casalegno Jean-Sébastien,Vaux Sophie,Cauchemez Simon

Funder

European Commission

ANR

Publisher

Elsevier BV

Reference24 articles.

1. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis;Li;Lancet,2022

2. Estimating the burden of respiratory syncytial virus (RSV) on respiratory hospital admissions in children less than five years of age in England, 2007–2012;Reeves;Influenza Other Respi Viruses,2017

3. Burden of respiratory syncytial virus in the European Union: estimation of RSV-associated hospitalizations in children under 5 years;Del Riccio;J Infect Dis,2023

4. Bronchiolitis viruses;Freymuth;Arch Pediatr,2010

5. Risk factors in children hospitalized with RSV bronchiolitis versus non-RSV bronchiolitis;García;Pediatrics,2010

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunomodulatory markers and therapies for the management of infant respiratory syncytial virus infection;Expert Review of Anti-infective Therapy;2024-09-13